PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
about
Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status ConsiderationsThe Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolismrs1495741 as a tag single nucleotide polymorphism of N-acetyltransferase 2 acetylator phenotype associates bladder cancer risk and interacts with smoking: A systematic review and meta-analysis.Improved drug therapy: triangulating phenomics with genomics and metabolomics.Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.Variation in NAT2 acetylation phenotypes is associated with differences in food-producing subsistence modes and ecoregions in Africa.Homologues of xenobiotic metabolizing N-acetyltransferases in plant-associated fungi: Novel functions for an old enzyme family.Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients.Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype.Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of isoniazid in cryopreserved human hepatocytes.PharmGKB summary: isoniazid pathway, pharmacokinetics.Role of N-acetyltransferase 2 acetylation polymorphism in 4, 4'-methylene bis (2-chloroaniline) biotransformation.Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).N-Acetyltransferase 2 Genotype-Dependent N-Acetylation of Hydralazine in Human Hepatocytes.Catalytic properties and heat stabilities of novel recombinant human N-acetyltransferase 2 allozymes support existence of genetic heterogeneity within the slow acetylator phenotype.Genetic heterogeneity among slow acetylator N-acetyltransferase 2 phenotypes in cryopreserved human hepatocytes.Association between the PINX1 and NAT2 polymorphisms and serum lipid levels.Effect of acetaminophen on sulfamethazine acetylation in male volunteers.Role of the N-acetylation polymorphism in solithromycin metabolism.N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians.Retrospective analysis of estrogen receptor 1 and N‑acetyltransferase gene expression in normal breast tissue, primary breast tumors, and established breast cancer cell lines.The fecal metabolome as a functional readout of the gut microbiome
P2860
Q28079207-10381481-6497-400D-B882-5949A0DADAEBQ28822540-E7882762-191E-49DD-B9AD-68686DE48809Q30248611-DBCC40FA-51A4-48EB-B2CE-E587FD0B2DD7Q34436487-C586350E-7E10-485E-B9A4-4CA8D329F8E0Q35661209-9995D836-CB91-453B-96A5-0D18381EAFEEQ35856283-031FCECB-7780-452F-98F5-10D2BD23ABEDQ35973985-27DBEF6F-C588-4E15-AD53-57A6013F65FDQ36075981-CBAB9D6E-2A97-4FC2-AC0D-1DF4A972FC6DQ37030180-DA9D6CA9-39FF-4875-9BE5-CDD84E5EEBDAQ37547290-7BF9FCB5-7C37-4B29-97A1-83628BB32349Q41068782-B60E8B03-A185-4654-B706-F69079145BF2Q42090708-A3666D39-6710-46C7-8452-CD5F9C4F3434Q47359205-AFC7AEEF-B855-4B83-8D4B-1520067AB63CQ47665232-2C4F58F3-E578-4584-9B11-02363F967156Q47669406-28CC1899-24B8-4B2B-ABE7-1DB2EA8102E6Q48123467-B1AE1DC7-B5DA-44D1-BB5C-A40D30AAFAA4Q48129221-0CE5C923-0FDE-481B-B7B6-C5865B1C2E6AQ49294719-51F620B2-B2A8-4CF1-9747-955E48FACC1CQ55013213-10EB8753-7217-4335-BD1B-94F151A1C2E5Q55154837-218CFBD9-832D-4D4D-B19F-D143E4C20EE8Q55376625-D22FDB02-9DDE-484B-AF60-D69287DC9C79Q55503255-AAC2C898-2773-4359-A1BA-AFA3EB244E23Q56102779-4F3BF9E5-B1EA-4E8B-90C9-4A1D4385D2D9
P2860
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
@ast
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
@en
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
@nl
type
label
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
@ast
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
@en
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
@nl
prefLabel
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
@ast
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
@en
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
@nl
P2860
P50
P3181
P1476
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
@en
P2093
Sotiria Boukouvala
Teri E. Klein
P2860
P304
P3181
P356
10.1097/FPC.0000000000000062
P407
P577
2014-08-01T00:00:00Z